乳腺癌保乳术后放疗不同固定方式的比较

目的 分析比较乳腺癌保乳术后放疗不同固定方式的摆位精度差异。方法 回顾性选取北京医院2021年1—8月乳腺癌保乳术后接受放疗的患者60例,其中30例采用多功能体板联合改良型体膜固定(改良型体膜组),30例采用真空垫固定(真空垫组)。比较两组的摆位误差、三维矢量误差、>5 mm误差的比例,以及计划靶区(PTV)和临床靶区(CTV)在模拟移床前后的剂量差异(包括PTV_V₁₀₀、PTV_V₉₅、CTV_V₉₅和模拟移床以后的PTV_V_100S、PTV_V_95S、 CTV_V_95S),并进一步分析改良型体膜组不同放疗时间的摆位误差变化。结果 60例患者共行锥形束CT扫描369次,其中改良型体膜组195次,真空垫组174次。两组x、y、z方向(左右、头脚、腹背)的摆位误差分别为(2.59±1.98)、(2.38±2.04)、(1.45±1.16)mm和(2.24±1.63)、(2.78±2.17)、(2.70±1.88)mm,三维矢量误差分别为(4.32±2.28)、(5.13±2.14)mm。其中,改良型体膜组在z方向和三维矢量上误差小于真空垫组(t=-7.77、-3.41, P＜0.05)。 >5 mm误差出现的比例,真空垫组在x方向低于改良型体膜组(χ² =7.13,P＜0.05),改良型体膜组在z方向低于真空垫组(χ²=5.90,P＜0.05)。模拟移床后,改良型体膜组的PTV_V_100S优于于真空垫组(t=2.47,P＜0.05)。且改良型体膜组第1周的x方向误差大于第2~3周和第4~5周(P＜0.05)。结论 使用多功能体板联合改良型体膜固定总体效果优于单纯使用真空垫固定,但应特别注意放疗第1周x方向的误差。     

Long-term results after 12-year follow-up of patients treated with whole-breast and boost irradiation after breast-conserving surgery

Purpose

The long-term outcomes of whole-breast and boost irradiation after breast-conserving surgery (BCS) for patients with breast cancer were retrospectively analyzed.

Materials and methods

Patients who received whole-breast and boost irradiation after BCS from 1990 to 2002 were included. Boost irradiation was administered to each tumor bed, regardless of the surgical margin status. The median doses of whole-breast and boost irradiation were 45 Gy in 25 fractions (range 36–45 Gy), and 14 Gy in 7 fractions (range 0–14 Gy), respectively.

Results

Data for 306 patients were analyzed. With a median follow-up time of 144 months, the 10-year overall survival, disease-free survival, ipsilateral breast tumor recurrence (IBTR), and metachronous contralateral breast cancer (MCBC) occurrence rates were 93.0, 84.1, 2.1, and 4.1 %, respectively. In the multivariate analysis, pT2 was a significant risk factor for IBTR (p = 0.041), while age ≤ 50 years and pT2 were significant risk factors for MCBC occurrence (p = 0.003 and 0.043, respectively). One patient (0.3 %) developed angiosarcoma in the irradiated region 120 months after the completion of radiation therapy.

Conclusion

The 12-year outcome of breast-conserving therapy using whole-breast and boost irradiation with doses of 45 and 14 Gy, respectively, was favorable.

     

保乳术后放疗影响标记夹几何体变化的相关因素分析

目的探讨保乳术后全乳调强放疗中标记夹所形成几何体体积、位置、形态的变化规律及相关影响因素。方法回顾性分析2021年10月至2022年9月苏州大学附属第一医院18例保乳术后调强放疗患者, 依据定位CT和放疗0、10、20、30、40、50 Gy时的锥形束CT(CBCT), 读取瘤床标记夹坐标信息, 获取每次摆位误差。利用凸包计算程序构建几何体, 分别计算出几何体基于定位CT的体积(Vct)、6次CBCT的体积(V0～5);比较6次CBCT与定位CT的几何体质心位移(D0～5)和包含度(DI0～5)。照射剂量分别对V0～5、D0～5、DI0～5的影响采用配对t检验或秩和检验;D0～5分别与同次三维方向摆位误差的相关性, V0～5变化率均值(AV)、D0～5均值(AD)、DI0～5均值(ADI)分别与体质量指数(BMI)、全乳体积(VB)、乳轴高(H)、手术至放疗时间间隔(T)的相关性, 均采用Pearson相关分析;几何体所处象限(Q)和几何体于胸壁贴离状态(S)分别对AV、AD、ADI的影响采用单因素方差分析。结果 D5与D0、D1、D2差异均有统计学意义(t=-3.27、-4.52、-...     

Radiation therapy after breast-conserving surgery

The authors critically reviewed previous articles concerning the significance of breast irradiation following breast-conserving surgery in terms of the following subject items: indications for breast-conserving therapy, the significance and complications of breast irradiation, the timing of the start of breast irradiation, the significance of boost irradiation, the potential improvement of survival with systemic therapy plus breast irradiation, the significance of axillary dissection, indications and the significance of regional nodal irradiation, accelerated hypofractionated radiotherapy, omission of breast irradiation in low-risk patients, and future directions. In addition, our previously reported results of breast irradiation following breast-conserving surgery at the Keio University Hospital are outlined. Our newly developed tangential irradiation technique directed to the axilla and a recently introduced three-dimensional simulation technique for radiotherapy treatment planning are also presented. This work was presented as an educational lecture at the 64^th Japan Radiological Society meeting in April 2005.     

The introduction of a newly developed radiation table for optimized radiotherapy after breast-conserving surgery

The half-side position is qualified for the radiation after breast-conserving therapy. By this we have a favourable position of the breast without pleats lateral or in the submammary region. To optimize the radiotherapy we developed a new radiation table. This table guarantees a free choosable half-side position of the patient respectively the breast reproducible every time. Until today we have used successful this new developed radiation table at 48 patients after breast-conserving therapy.     

3种不同放疗技术在左侧乳腺癌保乳术后全乳腺放疗中的剂量学比较

目的 比较3种调强放疗技术在早期左侧乳腺癌保乳术后全乳腺放疗中的剂量学差异。 方法 回顾性分析2019年3月至8月在西安交通大学第一附属医院治疗的12例早期左侧乳腺癌保乳术后女性患者,年龄32~50（42.4±6.8）岁。分别设计基于固定角度适形调强放疗的混合调强（3DCRT+IMRT）、容积旋转调强放疗的混合调强（3DCRT+VMAT）和切线弧容积旋转调强放疗计划（t-VMAT）,并比较3种放疗计划的计划靶区、危及器官剂量参数以及治疗效率的差异。组间数据比较采用配对t检验。 结果 3种调强放疗计划的靶区剂量分布和危及器官受量均能满足临床要求。3DCRT+IMRT和t-VMAT两种计划相比,3DCRT+VMAT的靶区剂量学指标适形性指数（0.84±0.05对0.74±0.06对0.79±0.06）和均匀性指数（0.10±0.03对0.14±0.03对0.13±0.03）最优,差异均有统计学意义（t=−9.01~6.47,均P<0.05）;3DCRT+IMRT对患侧（左）肺的V5[（35.92±8.01）%对（49.33±12.05）%对（60.58±12.94）%]、V10[（25.50±6.91）%对(26.92±7.23）%对（41.25±10.37）%]、Dmean[（10.14±2.43）Gy对（11.07±2.88）Gy对（14.52±3.32）Gy]和健侧（右）肺的V5[（0.50±1.45）%对（2.17±3.76）%对（3.00±4.94）%]、Dmean[（0.55±0.21）Gy对（1.79±0.58）Gy对1.75±0.70）Gy]及健侧（右）乳腺的V5[（0.17±0.58）%对（1.92±4.10）%对（8.25±8.61）%]、Dmean[（0.86±0.38）%对（1.65±0.45）%对（2.46±0.86）%]的保护最好。3DCRT+VMAT的心脏V30[（4.50±2.88）%对（5.00±3.25）%对（8.42±2.78）%]、V40[（2.50±2.11）%对（3.25±2.53）%对（4.58±2.07）%]明显优于3DCRT+IMRT和t-VMAT,且差异均有统计学意义（t=−17.11~3.45,均P<0.05）。3DCRT+IMRT的平均机器跳数最小（280.90±52.18）,t-VMAT的治疗时间最短。 结论 3DCRT+IMRT在低剂量区（<20 Gy）对健侧肺、患侧肺,健侧乳腺等危及器官的保护比较好,3DCRT+VMAT在提高靶区的均匀性和适形性方面有明显优势,且在高剂量区（>20 Gy）对患侧肺及心脏保护更好,t-VMAT缩短了治疗时间,提高了治疗效率和患者舒适度。     

乳腺癌保乳术后静态逆向调强与三维适形野中野放疗的剂量学比较

目的 比较早期乳腺癌保乳术后静态逆向调强(IMRT)与三维适形野中野瘤床同步加量(FIF)两种放疗技术的剂量学差异。方法 选择9例左侧早期乳腺癌保乳术后患者,分别设计IMRT与FIF两组放疗计划,处方剂量为乳房靶区50.4 Gy,分28次,每次1.8 Gy;瘤床靶区61.6 Gy,分28次,每次2.2 Gy。比较两组计划的靶区适形度及危及器官受量,并比较两者的计划优化和治疗时间。结果 IMRT的全乳靶区适形度(CI)为1.82±0.16,低于FIF的2.21±0.15(t=2.08,P<0.05);瘤床靶区适形度为1.19±0.04,低于FIF的1.59±0.11(t=3.97,P<0.05)。两组计划危及器官同侧肺的V₂₀和心脏的V₃₀无明显差异。FIF对侧肺的Dmax和Dmean分别是(5.41±2.76)和(0.51±0.10) Gy, IMRT分别为(25.72±2.61)和(7.46±0.39) Gy(t=-22.44、-21.14,P<0.05)。对侧乳房的Dmax和Dmean,FIF为(8.50±5.61)和(0.46±0.11) Gy,IMRT为(27.73±4.29)和(6.38±0.48) Gy(t=-5.66、-14.83,P<0.05)。对于对侧肺和乳房的低剂量照射区V₅,FIF为(0.09±0.09)%和(0.45±0.45)%,低于IMRT的(84.66±3.06)%和(60.79±4.94)%(t=-28.19、-12.80,P<0.05)。在计划优化及治疗时间方面,FIF与IMRT优化时间分别为(61.57±0.89)min和(241.28±1.06)min,单次治疗时间分别为(16.14±1.42)min和(29.85±0.59) min(t=-32.35、-8.82,P<0.05)。结论 IMRT改善了靶区适形度,但是增加了对侧肺和对侧乳房的受照剂量。FIF在计划优化时间及治疗时间方面有优势。     

快速旋转调强与五野动态调强在乳腺癌 保乳术后放疗中的剂量学比较

目的 比较乳腺癌保乳术后RapidArc计划与五野动态调强(5F-IMRT)计划的剂量学差异。方法 选择8例左侧乳腺癌保乳术后女性患者,处方剂量为50 Gy/ 25次。分别设计RapidArc计划与5F-IMRT计划。比较两种计划的靶区适形度指数、均匀性指数、靶区覆盖度和危及器官的受照剂量体积,同时比较两组计划实施时的治疗时间和机器跳数。结果 在两种计划的靶区比较中,RapidArc计划的靶区适形度指数为(0.88±0.03),高于5F-IMRT计划的(0.79±0.02)(t=8.28,P<0.05);RapidArc计划的均匀性指数为(9.01±0.73),优于5F-IMRT计划的(10.44±1.08)(t=-2.73,P<0.05)。两组计划在同侧肺受照剂量体积比较中RapidArc计划的D_mean、V₁₀、V₂₀、V₃₀小于5F-IMRT计划(t=-7.53、-7.20、-8.39、-7.80,P<0.05),但RapidArc计划中的V₅较5F-IMRT计划增加了约16% (t=5.67,P<0.05);心脏的受照剂量体积比较中RapidArc计划中的D_mean、V₅、V₁₀均高于5F-IMRT(t=10.46、28.76、5.40,P<0.05),但在RapidArc计划中心脏的V₃₀低于5F-IMRT (t=-6.12,P<0.05)。对侧肺和对侧乳腺的V₅在RapidArc计划中明显高于5F-IMRT计划 (肺:t=21.50,P<0.05;乳腺:t=5.44,P<0.05)。RapidArc计划中机器跳数减少了25%,平均治疗时间节省了60%。结论 乳腺癌保乳术后RapidArc计划与5F-IMRT计划比较提高了靶区的适形度和均匀度,减少了高剂量区的受照体积,降低了机器跳数,缩短了治疗时间,但增加了正常组织低剂量区的受照体积。     

吡柔比星用于乳腺癌术后新辅助化疗的安全性和有效性分析

目的探讨以吡柔比星为主的化疗方案应用于乳腺癌治疗的安全和有效性。方法将本院2011年1月—2012年6月诊治的96例局部晚期乳腺癌患者随机分成两组：对照组48例,采用多柔比星为主的新辅助化疗方案;试验组48例,采用吡柔比星为主的新辅助化疗方案。观察和比较两组的化疗效果和不良反应。结果试验组和对照组的总缓解率分别为81．25％、77．08％,两组疗效比较差异无统计学意义（P〉0．05）;试验组的心脏毒性、脱发的发生率分别为16．67％、39．58％,对照组的心脏毒性、脱发的发生率分别为35．42％、77．08％,试验组的。tk,脏毒性、脱发的发生率明显低于对照组（P〈0．05）。结论吡柔比星联合化疗治疗局部晚期乳腺癌比多柔比星更安全可靠。     

Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response

Objectives

To correlate the decrease in background parenchymal enhancement (BPE) and tumour response measured with MRI in breast cancer patients treated with neoadjuvant chemotherapy (NAC).

Methods

One hundred and forty-six MRI examinations of 73 patients with 80 biopsy-proven breast cancers who underwent breast MRI before and after NAC were retrospectively analysed. All images were reviewed by two blinded readers, who classified BPE into categories (BEC; 1?=?minimal, 2?=?mild, 3?=?moderate, 4?=?marked) before and after NAC. Histopathological and morphological tumour responses were analysed and compared.

Results

The distribution of BEC 1/2/3/4 was 25/46/18/11 % before and 78/20/2/0 % after NAC. On average, BPE decreased by 0.87 BEC. Cohen’s kappa showed substantial agreement (k?=?0.73–0.77) before and moderate agreement (k?=?0.43–0.60) after NAC and moderate agreement (k?=?0.62–0.60) concerning the change in BEC. Correlating the change in BPE with tumour response, the average decrease in BEC was 1.3 in cases of complete remission, 0.83 in cases with partial response, 0.85 in cases with stable disease and 0.40 in cases with progressive disease. Correlation analysis showed a significant correlation between the decrease in BEC and tumour response (r?=??0.24, p?=?0.03).

Conclusions

BPE decreased by, on average, 0.87 BEC following NAC for breast cancer. The degree of BPE reduction seemed to correlate with tumour response.

Key Points

? BPE decreases by an average of 0.87 categories under neoadjuvant chemotherapy. ? The reduction of BPE following neoadjuvant chemotherapy correlates with the tumour response. ? The classification of the BPE shows good agreement among trained readers.

     

Mammographic follow-up after breast conserving surgery and postoperative radiotherapy without boost irradiation for mammary carcinoma

Pre- and postoperative mammograms were reviewed in 103 women undergoing conservation surgery and irradiation for breast cancer stage I. The main reactions to radiotherapy were increased breast parenchymal density and increased skin thickness. Changes reached a peak at 9 months. No new changes were seen at 2 years, and most had regressed at this time. Following surgery, 71 of the patients displayed noticeable scar tissue in the surgical area, sometimes causing diagnostic difficulties. Two of the patients had a local recurrence of carcinoma, while 3 developed cancer in the other breast.     

Emerging technology for intraoperative margin assessment and post-operative tissue diagnosis for breast-conserving surgery

IntroductionTissue-preserving surgery is utilized progressively in cancer therapy, where a clear surgical margin is critical to avoid cancer recurrence, specifically in breast cancer (BC) surgery. The Intraoperative pathologic approaches that rely on tissue segmenting and staining have been recognized as the ground truth for BC diagnosis. Nevertheless, these methods are constrained by its complication and timewasting for tissue preparation.ObjectiveWe present a non-invasive optical imaging system incorporating a hyperspectral (HS) camera to discriminate between cancerous and non-cancerous tissues in ex-vivo breast specimens, which could be an intraoperative diagnostic technique to aid surgeons during surgery and later a valuable tool to assist pathologists.MethodsWe have established a hyperspectral Imaging (HSI) system comprising a push-broom HS camera at wavelength 380∼1050 nm with source light 390∼980 nm. We have measured the investigated samples' diffuse reflectance (R_d), fixed on slides from 30 distinct patients incorporating mutually normal and ductal carcinoma tissue. The samples were divided into two groups, stained tissues during the surgery (control group) and unstained samples (test group), both captured with the HSI system in the visible and near-infrared (VIS-NIR) range. Then, to address the problem of the spectral nonuniformity of the illumination device and the influence of the dark current, the radiance data were normalized to yield the radiance of the specimen and neutralize the intensity effect to focus on the spectral reflectance shift for each tissue. The selection of the threshold window from the measured R_d is carried out by exploiting the statistical analysis by calculating each region's mean and standard deviation. Afterward, we selected the optimum spectral images from the HS data cube to apply a custom K-means algorithm and contour delineation to identify the regular districts from the BC regions.ResultsWe noticed that the measured spectral R_d for the malignant tissues of the investigated case studies versus the reference source light varies regarding the cancer stage, as sometimes the R_d is higher for the tumor or vice versa for the normal tissue. Later, from the analysis of the whole samples, we found that the most appropriate wavelength for the BC tissues was 447 nm, which was highly reflected versus the normal tissue. However, the most convenient one for the normal tissue was at 545 nm with high reflection versus the BC tissue. Finally, we implement a moving average filter for noise reduction and a custom K-means clustering algorithm on the selected two spectral images (447, 551 nm) to identify the various regions and effectively-identified spectral tissue variations with a sensitivity of 98.95%, and specificity of 98.44%. A pathologist later confirmed these outcomes as the ground truth for the tissue sample investigations.ConclusionsThe proposed system could help the surgeon and the pathologist identify the cancerous tissue margins from the non-cancerous tissue with a non-invasive, rapid, and minimum time method achieving high sensitivity up to 98.95%.     

Early mammographic and sonographic findings after intraoperative radiotherapy (IORT) as a boost in patients with breast cancer

The aim of this study was to evaluate mammographic and sonographic changes at the surgical site within the first 2 years after IORT as a boost followed by whole-breast radiotherapy (WBRT), compared with a control group treated with WBRT alone. All patients had breast-conserving surgery for early-stage breast cancer. Group A: n = 27, IORT (20 Gy) followed by WBRT (46 Gy). Group B (control group): n = 27, WBRT alone (56-66 Gy). Mammography: fat necrosis in 14 group A versus four group B patients (P < 0.001); parenchymal scarring classified as unorganized at the last follow-up in 16 vs seven cases, respectively (P = 0.03). Ultrasound: overall number of patients with circumscribed findings 27 vs 18 (P < 0.001); particular hematomas/seromas in 26 vs 13 patients (P < 0.001). Synopsis of mammography and ultrasound: overall postoperative changes were significantly higher classified in group A (P = 0.01), but not judged to have a significantly higher impact on interpretation. Additional diagnostic procedures, due to unclear findings at the surgical site, were performed on four patients of both groups. Within the first 2 years after IORT as a boost, therapy-induced changes at the original tumor site are significantly more pronounced compared with a control group. There is no evidence that the interpretation of findings is complicated after IORT.     

MRI predictors of tumor-positive margins after breast-conserving surgery

PurposeThe purpose of this study is to identify predictors of tumor-positive surgical margins after breast-conserving surgery on dynamic contrast-enhanced (DCE) MRI.Materials and methodsWe conducted a retrospective study of consecutive women who underwent DCE MRI before breast-conserving surgery from 2005 to 2014. Patient demographics, indication for surgery, MRI findings, biopsy pathology results, and surgical outcomes were reviewed. The unpaired t-test and chi-square test were used to compare the positive and negative margins groups.Results554 women (mean age, 56; range, 26–90) underwent DCE MRI before 575 breast-conserving surgeries for invasive carcinoma (n = 473) or ductal carcinoma in situ (DCIS) (n = 102). Positive margins requiring re-excision occurred in 19.7% (93/473) of surgeries for invasive carcinoma and 31.4% (32/102) of surgeries for DCIS. For invasive carcinoma surgeries, positive margins were more common when MRI demonstrated the finding of non-mass enhancement (NME) rather than the finding of enhancing mass (33.8% [22/65] versus 16.9% [61/360], p < 0.01). Tumor size on MRI was significantly larger in the positive margins group (2.5 cm versus 1.9 cm, p < 0.001). Positive margins were more common with invasive lobular rather than invasive ductal histology at core biopsy (38.3% [18/47] versus 16.0% [56/350], p < 0.001). For DCIS surgeries, there were no significant differences in positive margin rates related to MRI features.ConclusionFor invasive carcinoma surgeries, positive margins are associated with NME on MRI, larger tumor size on MRI, and lobular histology at core biopsy. These findings may be used to predict which patients are at risk for positive margins after breast-conserving surgery.     

TomoDirect和TomoHelical技术在左侧乳腺癌保乳术后放疗中的剂量学比较

目的 比较4野和6野断层定野照射（TomoDirect）及断层螺旋照射（TomoHelical）技术在左侧乳腺癌保乳术后患者的放疗计划应用中的剂量学差异。方法 作为回顾性研究,本文选取16例已行调强（IMRT）治疗的左侧乳腺癌保乳术后患者,在螺旋断层放疗（Tomotherapy）计划系统上分别进行4野和6野的TomoDirect及TomoHelical 3种技术的模拟计划,比较3种技术设计的计划靶区和危及器官的剂量学差异及治疗参数。结果 3种技术设计的乳腺癌计划,均能满足临床要求。其中,4野TomoDirect技术对危及器官和正常组织,尤其是脊髓、健侧乳腺最大剂量D_max,肺的V₅,心脏D_mean（F=595.60、129.24、60.44、65.37,P<0.05）的保护优于TomoHelical技术,但在靶区剂量均匀性和适形度方面,以TomoHelical技术较优（F=2.78、60.93,P<0.05）。6野TomoDirect技术,在保证较TomoHelical技术低的危及器官限量的条件下,提高了4野TomoDirect技术的靶区均匀性和适形度。此外,TomoDirect技术的机器跳数均优于TomoHelical技术,有效地减少了患者治疗时间（F=24.89、3.75,P<0.05）。结论 对于左侧乳腺癌保乳术后放疗,6野TomoDirect技术设计的计划具有一定优势,与TomoHelical技术相比,6野TomoDirect大大降低了危及器官受量;与4野TomoDirect技术相比,6野TomoDirect靶区均匀性和适形度较优,更适宜于早期乳腺癌患者。     

乳腺癌保乳术后全乳加瘤床补量照射不同治疗计划的比较

目的 探讨乳腺癌保乳术后全乳加瘤床照射不同治疗计划靶区剂量适形度、靶区剂量分布均匀性及肺脏、心脏和对侧乳腺受照剂量体积的差异。方法 选择术腔各边界放置银夹且无腋窝淋巴结转移的12 例左侧乳腺癌保乳术后患者, 每例患者分别制定常规放疗(CRT)、无挡肺子野调强放疗(IMRT-F)、挡肺子野调强(IMRT-F-L) 和瘤床同步整合补量调强放疗(SIB-IMRT) 计划。比较不同治疗计划全乳靶区和瘤床靶区的剂量适形度和剂量分布均匀性, 对比不同治疗计划肺脏、心脏和对侧乳腺受照剂量体积。结果 各计划中V_{处方剂量- PTV}1 V_PTV1、V_PTV1 处方剂量 V_PTV2、V_{处方剂量-PTV2 V- 处方剂量、VPTV2-处方剂量 VPTV2组间差异均有统计学意义;CRT 计划中患侧肺V20显著高于不同方式的IMRT 计划, 但不同方式的IMRT 计划之间V20差异无统计学意义;CRT 计划中心脏受照剂量显著高于IMRT 和SIB-I MRT 计划。CRT 计划中对侧乳腺最大照射剂量 Dmax和平均剂量Dmean明显高于不同实现方式的IMRT计划, 但不同实现方式的IMRT 计划中 Dmax和Dmean差异无统计学意义。结论 IMRT-F、IMRT-F-L、SIB-I MRT 计划均显著优于 CRT 计划, 而不同方式I MRT 计划间除个别参数外差异无统计学意义。}     

术前新辅助化疗结合保乳术治疗中晚期乳腺癌

目的观察多西紫杉醇+阿霉素+环磷酰胺(TAC)方案新辅助化疗治疗中晚期乳腺癌的疗效和毒副反应并探讨该方案后行保乳术治疗的可行性。方法对2004年2月—2009年12月我院收治的一些有强烈保乳意愿的中晚期乳腺癌患者进行3～4个疗程TAC方案治疗,疗程结束后评价疗效和毒副反应;选取24例达到保乳指征的患者行保乳术,作为保乳组,随机抽取我院同期收治的35例未作新辅助化疗而直接行乳房根治术的中晚期患者作为对照组,从乳房满意度、局部复发率、远处转移率和5年生存率比较两组的疗效。结果化疗完成后,保乳组完全缓解(CR)4例,部分缓解(PR)15例,总有效率为79.2%;毒副反应以白细胞下降、恶心和(或)呕吐以及脱发为主,对症治疗后缓解;保乳组的乳房满意度、局部复发率、远处转移率和5年生存率分别为91.7%、12.5%、8.3%、87.5%,对照组相应的数据分别为0、5.7%、20%、88.6%。结论通过TAC方案治疗后满足保乳指征的中晚期乳腺癌患者,行保乳术治疗是一种安全可行的方法。     

Longitudinal practical measurement of skin color and moisture during and after breast-conserving therapy: influence of neoadjuvant systemic therapy

Purpose  

The aim of this study was to assess radiation dermatitis, especially exploring the influence of neoadjuvant systemic therapy (NST).     

早期乳腺癌保乳术后加速部分乳腺照射对比全乳腺照射瘤床推量照射的临床研究

目的 对比早期乳腺癌保乳术后加速部分乳腺照射（ABPI）和全乳腺照射瘤床同步推量照射（WBI-SIB）两种放射治疗模式的临床疗效,从经济学角度进行分析,为术后辅助放疗模式的选择提供参考。方法 回顾性分析355例早期乳腺癌保乳术后放疗患者。其中177例患者接受ABPI,178例患者接受WBI-SIB。计算生存率,放疗不良反应采用NCI-CTC 3.0评估,美容评价依据Harris美容级别标准,并进行成本分析。结果 中位随访42个月（5.8~92.7个月）。ABPI组和WBI-SIB组的3年无局部区域复发生存率（LRFS）分别为98.2%和97.6%,无远处转移生存率（DMFS）分别为94.3%和93.7%,无疾病进展生存率（DFS）分别为93.1%和91.6%,总生存率分别为95.5%和94.3%,差异均无统计学意义（P>0.05）。与WBI-SIB组相比,ABPI组的2级以上急性不良反应发生率由5.6%降至3.4%（χ²=6.044,P<0.05）,2级以上晚期不良反应由5.6%降至2.3%（χ²=6.149,P<0.05）,美容效果优良率由88.8%提高到93.8%（χ²=5.22,P<0.05）,且平均治疗时间由36.2 d缩短了26.5 d（χ²=40.76,P<0.05）。结论 早期乳腺癌保乳术后ABPI和WBI-SIB的临床疗效相似,前者的急性和晚期不良反应更低,美容效果更佳,经济成本更低,可作为早期乳腺癌保乳术后放疗治疗模式的良好选择。